M Mehling
Overview
Explore the profile of M Mehling including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
469
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Susey K, Hanin M, Wortner A, Mandich M, Scott K, Stephenson K, et al.
J Perinatol
. 2023 May;
43(8):1015-1019.
PMID: 37185368
Objective: There is no reliable evidence on how best to evaluate the overall status of infants with severe forms of bronchopulmonary dysplasia (BPD). The Behavioral Signs of Respiratory Instability (BSRI)...
2.
Naegelin Y, Rasenack M, Andelova M, von Felten S, Fischer-Barnicol B, Amann M, et al.
Mult Scler Relat Disord
. 2018 Jul;
25:14-20.
PMID: 30014876
Background: There is limited evidence about the optimal length of washout when switching from natalizumab to fingolimod. Objective: To study if a washout period of 4 weeks is associated with...
3.
Mehling M, Burgener A, Brinkmann V, Bantug G, Dimeloe S, Hoenger G, et al.
Scand J Immunol
. 2015 Aug;
82(5):460-6.
PMID: 26285786
Human natural killer (NK) cell subsets differentially distribute throughout the organism. While CD56(dim) and CD56(bright) NK cell subsets similarly reside in the bone marrow (BM), the CD56(dim) population predominantly accumulates...
4.
Hegen H, Millonig A, Bertolotto A, Comabella M, Giovanonni G, Guger M, et al.
Mult Scler
. 2013 Sep;
20(5):577-87.
PMID: 24009164
Background: Neutralizing antibodies (NAb) affect efficacy of interferon-beta (IFN-b) treatment in multiple sclerosis (MS) patients. NAbs evolve in up to 44% of treated patients, usually between 6-18 months on therapy....
5.
Kuhle J, Leppert D, Petzold A, Regeniter A, Schindler C, Mehling M, et al.
Neurology
. 2011 Feb;
76(14):1206-13.
PMID: 21346223
Objective: Neurodegeneration is now accepted as a pathologic hallmark of multiple sclerosis (MS). We sought to discover whether CSF levels of neurofilament heavy chain protein (NfH(SMI35)) correlate with disability, disease...
6.
Mehling M, Johnson T, Antel J, Kappos L, Bar-Or A
Neurology
. 2011 Feb;
76(8 Suppl 3):S20-7.
PMID: 21339487
The oral sphingosine 1-phosphate (S1P) receptor (S1PR) modulator fingolimod has been shown to be effective in the treatment of patients with relapsing multiple sclerosis (MS). The drug binds with high...
7.
Mehling M, Lindberg R, Raulf F, Kuhle J, Hess C, Kappos L, et al.
Neurology
. 2010 Jul;
75(5):403-10.
PMID: 20592255
Objective: FTY720 is a sphingosine 1-phosphate (S1P) receptor modulator that showed efficacy in phase II and III clinical trials in patients with multiple sclerosis (MS). FTY720 inhibits lymphocyte egress from...
8.
Kochkorov A, Gugleta K, Kavroulaki D, Katamay R, Weier K, Mehling M, et al.
Klin Monbl Augenheilkd
. 2009 Apr;
226(4):276-9.
PMID: 19384782
Purpose: The aim of this study was to analyze pulse wave propagation in the ocular circulation by assessing the phase delay between retinal arterioles and venules and calculating the pulse...
9.
Gugleta K, Kochkorov A, Kavroulaki D, Katamay R, Weier K, Mehling M, et al.
Klin Monbl Augenheilkd
. 2009 Apr;
226(4):272-5.
PMID: 19384781
Background: Transparency of ocular media enables the precise quantitative analysis of vessels of retina, a neuronal tissue which can be affected by multiple sclerosis (MS). Patients And Methods: Eyes with...
10.
Kuhle J, Lindberg R, Regeniter A, Mehling M, Steck A, Kappos L, et al.
Eur J Neurol
. 2009 Feb;
16(6):771-4.
PMID: 19236470
Background And Purpose: Amyotrophic lateral sclerosis (ALS) is classically assumed to be a neurodegenerative disorder. Inflammation has been observed in CNS tissue in ALS patients. We investigated the expression and...